Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 12 74 54 43 15 17 71 32
Fear of Open Spaces 12

Classifications:



External Ids:

Disease Ontology 12 DOID:593
MeSH 43 D000379
NCIt 49 C34362
SNOMED-CT 67 70691001
ICD10 32 F40.0
UMLS 71 C0001818

Summaries for Agoraphobia

Disease Ontology : 12 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to depression and personality disorder. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Serotonergic synapse and Imipramine/Desipramine Pathway, Pharmacokinetics. The drugs Vortioxetine and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 depression 31.7 SLC6A4 MAOA HTR1A
2 personality disorder 31.3 SLC6A4 MAOA HTR1A COMT
3 neurotic disorder 31.0 SLC6A4 MAOA HTR1A
4 generalized anxiety disorder 30.9 SLC6A4 SLC6A2 MAOA HTR1A COMT
5 obsessive-compulsive disorder 30.9 SLC6A4 PTK7 MAOA HTR1A COMT
6 hypochondriasis 30.9 SLC6A4 PIR IVL HTR1A
7 avoidant personality disorder 30.9 WASF2 WASF1 SLC6A4 PIR MAOA
8 phobic disorder 30.8 WASF2 WASF1 SLC6A4 PIR NBAS MAOA
9 eating disorder 30.8 SLC6A4 HCRTR1 COMT
10 separation anxiety disorder 30.7 WASF2 WASF1 SLC6A4 NBAS
11 panic disorder 30.7 TMEM132D SLC6A4 SLC6A2 PTK7 MIR22 MAOA
12 anxiety 30.6 TMEM132D SLC6A4 SLC6A2 PTK7 MAOA HTR1A
13 melancholia 30.6 SLC6A4 MAOA LOC110806262 HTR1A
14 dependent personality disorder 30.6 WASF2 WASF1 PIR
15 endogenous depression 30.5 WASF1 SLC6A4 MAOA HTR1A COMT
16 atypical depressive disorder 30.5 SLC6A4 MAOA HTR1A
17 irritable bowel syndrome 30.5 SLC6A4 HTR1A COMT
18 mood disorder 30.5 SLC6A4 SLC6A2 MAOA HTR1A COMT
19 bulimia nervosa 30.5 SLC6A4 MAOA COMT
20 sleep disorder 30.5 SLC6A4 HTR1A HCRTR1
21 alcohol use disorder 30.4 WASF2 WASF1 SLC6A4 HTR1A COMT
22 alcohol dependence 30.3 SLC6A4 SLC6A2 MAOA HTR1A COMT CCKBR
23 mental depression 30.3 WASF2 WASF1 SLC6A4 SLC6A2 MAOA HTR1A
24 histrionic personality disorder 30.2 WASF2 WASF1 PIR
25 constipation 30.2 SLC6A4 SLC6A2 HTR1A GRP
26 tic disorder 30.2 SLC6A4 MAOA HTR1A COMT
27 borderline personality disorder 30.2 SLC6A4 MAOA HTR1A COMT
28 post-traumatic stress disorder 30.1 SLC6A4 MAOA HTR1A COMT
29 major depressive disorder 30.1 TMEM132D SLC6A4 SLC6A2 MAOA HTR1A HCRTR1
30 obsessive-compulsive personality disorder 30.1 WASF2 WASF1 SLC6A4 PIR COMT
31 cyclothymic disorder 30.1 PIR COMT
32 bipolar disorder 30.1 SLC6A4 SLC6A2 MAOA HTR1A COMT
33 tobacco addiction 29.8 WASF2 WASF1 SLC6A4 MAOA COMT
34 attention deficit-hyperactivity disorder 29.7 SLC6A4 SLC6A2 MAOA HTR1A COMT
35 dysthymic disorder 29.7 WASF2 WASF1 SLC6A4 PIR MAOA IVL
36 disease of mental health 29.5 WASF2 WASF1 SLC6A4 MIR22 MAOA HTR1A
37 social phobia 29.4 WASF2 WASF1 SLC6A4 PTK7 NBAS MAOA
38 phobia, specific 29.1 WASF2 WASF1 TMEM132D SLC6A4 NBAS MAOA
39 panic disorder 1 11.8
40 inhibited male orgasm 10.5 SLC6A4 HTR1A
41 kleptomania 10.4 SLC6A4 MAOA HTR1A
42 pyromania 10.4 WASF1 MAOA
43 amphetamine abuse 10.4 SLC6A4 SLC6A2
44 psychosexual disorder 10.4 SLC6A4 HTR1A
45 severe combined immunodeficiency 10.4
46 serotonin syndrome 10.4 SLC6A4 MAOA HTR1A
47 exhibitionism 10.3 PIR MAOA
48 drug psychosis 10.3 HTR1A COMT
49 body dysmorphic disorder 10.3 SLC6A4 PIR MAOA
50 drug-induced mental disorder 10.3 HTR1A COMT

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to Agoraphobia

Symptoms & Phenotypes for Agoraphobia

GenomeRNAi Phenotypes related to Agoraphobia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.32 SLC6A4
2 Decreased viability GR00381-A-1 9.32 GRP HTR1A SLC6A4
3 Decreased viability GR00381-A-3 9.32 GRP HTR1A SLC6A4
4 Decreased viability GR00386-A-1 9.32 GRP
5 Decreased viability GR00402-S-2 9.32 GRP HTR1A

MGI Mouse Phenotypes related to Agoraphobia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 CCKBR COMT GRP GRPR HCRTR1 HTR1A
2 cardiovascular system MP:0005385 9.7 CCKBR COMT GRP HTR1A MAOA NBAS
3 nervous system MP:0003631 9.44 CCKBR COMT GRP HCRTR1 HTR1A MAOA

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
2
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
3
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
4
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
5
Citalopram Approved Phase 4 59729-33-8 2771
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
8
Sertraline Approved Phase 4 79617-96-2 68617
9
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
10
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12
Phenylalanine Approved, Investigational, Nutraceutical Phase 4 63-91-2 6140
13 Serotonin 5-HT1 Receptor Agonists Phase 4
14 Serotonin Receptor Agonists Phase 4
15 Serotonin 5-HT3 Receptor Antagonists Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Dopamine agonists Phase 4
18 Dopamine Antagonists Phase 4
19 Antipsychotic Agents Phase 4
20 Micronutrients Phase 4
21 Trace Elements Phase 4
22 Vitamins Phase 4
23 Hormones Phase 4
24 Nutrients Phase 4
25 Calciferol Phase 4
26 Calcium, Dietary Phase 4
27 Dopamine Agents Phase 4
28 Central Nervous System Stimulants Phase 4
29 Neurotransmitter Agents Phase 4
30 Antidepressive Agents Phase 4
31 Psychotropic Drugs Phase 4
32 Serotonin Uptake Inhibitors Phase 4
33 Hypnotics and Sedatives Phase 4
34 Anti-Anxiety Agents Phase 4
35 GABA Modulators Phase 4
36
Calcium Nutraceutical Phase 4 7440-70-2 271
37
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
38
Topiramate Approved Phase 2, Phase 3 97240-79-4 5284627
39 Hypoglycemic Agents Phase 2, Phase 3
40 Anticonvulsants Phase 3
41 Lecithin Phase 3
42 Sunflower Phase 3
43 Epidiolex Phase 3
44
Cycloserine Approved Phase 2 68-41-7 401 6234
45 Anti-Infective Agents Phase 2
46 Antitubercular Agents Phase 2
47 Anti-Bacterial Agents Phase 2
48 Antibiotics, Antitubercular Phase 2
49 Antimetabolites Phase 2
50
Adenosine Approved, Investigational 58-61-7 60961

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder Completed NCT02395510 Phase 4 Vortioxetine
2 Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
3 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
4 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
5 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Recruiting NCT03522844 Phase 4 Escitalopram
6 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
7 To Evaluate BH4 Responsiveness in PAH Deficiency PKU Patients Who Failed to Achieve 30% Blood Phe Reduction Within 24-hour BH4 Loading Test by Extending the Period of BH4 Response Test: A Pilot Study in Taiwan Not yet recruiting NCT04227080 Phase 4 BH4
8 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
9 An Open-Label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
10 Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure Unknown status NCT01323556 Phase 2, Phase 3
11 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
12 Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study Completed NCT00785135 Phase 3
13 Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial Completed NCT00845260 Phase 3
14 Dynamic Treatment vs. CBT for Panic Disorder Completed NCT00353470 Phase 3
15 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder Completed NCT00204386 Phase 2, Phase 3 Topiramate
16 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule
17 Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder Completed NCT01928823 Phase 2 D-Cycloserine
18 Intensive Treatment of Adolescent Panic and Agoraphobia Completed NCT00576719 Phase 2
19 Effects of Physical Exercise on Anxiety and Co-morbid Emotional Disturbances: A Clinical Trail in a Day Care Unit Completed NCT01076777 Phase 2
20 Exposure Therapy for Fear of Falling in Older Adults Completed NCT01609322 Phase 2
21 Exposure, D-Cycloserine Enhancement, and Genetic Modulators in Panic Disorder Completed NCT00790868 Phase 2 d-cycloserine;placebo
22 The Modular Protocol for Mental Health (MPMH): A Pilot Randomised Clinical Trial of a Transdiagnostic Psychological Treatment for Mood and Anxiety Disorders in Adults Active, not recruiting NCT03143634 Phase 1, Phase 2
23 An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study Of Xanax XR Tablet 3 mg (Sourced From Caguas) Versus Xanax XR Tablet 3 mg (Sourced From Barceloneta) In Healthy Subjects Completed NCT01330472 Phase 1 Xanax XR tablets 3 mg (sourced from Caugus);Xanax XR tablets 3 mg (sourced from Barceloneta)
24 A Comparative Controlled Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610
25 Virtual Reality and Concept of Control in the Treatment of Acrophobia by Exposure to Virtual Environments: Comparative Test Unknown status NCT02020824
26 Internet Based Self-help Therapy With FearFighter™ Versus no Intervention for Anxiety Disorders in Adult Persons: a Randomised Feasibility Trial Unknown status NCT02499055
27 Examining the Effects of Reduced Environmental Stimulation on Anxiety Unknown status NCT03051074
28 Interventionnal and Randomized Study Measuring Virtual Reality Cue Exposure for the Relapse Prevention of Tobacco Consumption Versus Cognitive and Behavioral Approaches Therapy Unknown status NCT02205060
29 The Assessment and Treatment of Balance Impairment Using Virtual Reality (VR) in Panic Disorder Patients Unknown status NCT01677429
30 Effects of Mindfulness Based Cognitive Therapy on Emotional Processing Unknown status NCT03358056
31 The Influence of Physical Activity (Prior to In-vivo Exposure) on the Effect of Cognitive Behavioural Therapy in Patients With Panic Disorder and Agoraphobia Completed NCT01928810
32 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367
33 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Panic Disroder and Agoraphobia Completed NCT01446172
34 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group. Completed NCT00202709
35 Thought Field Therapy and Cognitive Therapy for Agoraphobia - a Randomized Controlled Intervention Study Where the Efficacy of Thought Field Therapy is to be Compared to Cognitive Therapy Completed NCT00932919
36 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370
37 The Influence of Physical Activity on the Effect of Cognitive Behavioural Therapy, Neurobiological Parameters and Information Processing in Patients With Panic Disorder With/Without Agoraphobia Completed NCT01788800
38 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366
39 Effectiveness of Specific Model of Cognitive-Behavioral Therapy in Panic Disorder Patients With Agoraphobia Completed NCT00772746
40 Internet-based Exposure Therapy for Panic Disorder: A Randomized Controlled Pilot Study Completed NCT03061448
41 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
42 Open-label Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months Completed NCT00711737
43 A Pragmatic Randomized Controlled Trial of Group Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders in Primary Care Completed NCT02811458
44 Moderators and Mediators of Treatment Change in Panic Disorder and Agoraphobia Completed NCT03547180
45 Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction Completed NCT02605668
46 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak Completed NCT04351399
47 Phase 2 Randomized Controlled Trial of Attention and Interpretation Modification (AIM) for Anxiety Disorders in Primary Care Completed NCT02579915
48 Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway. A Randomized Controlled Study Completed NCT02150265
49 Neural Effects of Cognitive-behaviour Therapy in Panic Disorder Completed NCT03251235
50 Expanding Access to Therapy for Childhood Anxiety Disorders Via Smart Phones - PILOT Completed NCT02205177

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam

Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

Anatomical Context for Agoraphobia

MalaCards organs/tissues related to Agoraphobia:

40
Testes, Brain, Heart, Cortex, Thyroid, Amygdala, Pituitary

Publications for Agoraphobia

Articles related to Agoraphobia:

(show top 50) (show all 3041)
# Title Authors PMID Year
1
Associations between serotonin-related gene polymorphisms and panic disorder. 54 61
15670397 2005
2
Norepinephrine transporter (NET) promoter and 5'-UTR polymorphisms: association analysis in panic disorder. 61 54
15722184 2005
3
Association of a functional 1019C>G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia. 54 61
14984628 2004
4
Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. 61 54
10870873 2000
5
Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. 61 54
8771610 1996
6
A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. 54 61
7786960 1995
7
Manualized single-session behavior treatment with self-help manual for panic disorder with or without agoraphobia. 61
31510890 2020
8
Avoidance Moderates Cognitive Behavioral Therapy for Panic Disorder and Agoraphobia. 61
32544125 2020
9
Investigating gender-specific effects of familial risk for attention-deficit hyperactivity disorder and other neurodevelopmental disorders in the Swedish population. 61
32552921 2020
10
Effects of Dog Assisted Therapy for Adults with Autism Spectrum Disorder: An Exploratory Randomized Controlled Trial. 61
30900194 2020
11
Predicting the naturalistic course in anxiety disorders using clinical and biological markers: a machine learning approach. 61
32524918 2020
12
The Impact of Personality Pathology on Treatment Outcome in Late-life Panic Disorder. 61
32421288 2020
13
Psychological and demographic characteristics of 368 patients with dissociative seizures: data from the CODES cohort. 61
32389147 2020
14
Affective Styles in Panic Disorder and Specific Phobia: Changes Through Cognitive Behavior Therapy and Prediction of Remission. 61
32402254 2020
15
Family-based treatment for adolescent anorexia nervosa: What happens to rates of comorbid diagnoses? 61
31995262 2020
16
Subscales of the Fear Survey Schedule-III in Community Dwelling Older Adults - Relations to Clinical and Cognitive Measures. 61
30706768 2020
17
Cognitive behavioral group therapy for panic disorder in a general clinical setting: a prospective cohort study with 12 to 31-years follow-up. 61
32448206 2020
18
Psychiatric comorbidities in bipolar disorders: An examination of the prevalence and chronology of onset according to sex and bipolar subtype. 61
32217226 2020
19
Intensive one-week internet-delivered cognitive behavioral therapy for panic disorder and agoraphobia: A pilot study. 61
32257825 2020
20
Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome. 61
31954293 2020
21
The Influence of Socio-Demographic Factors, Lifestyle and Psychiatric Indicators on Adherence to Treatment of Patients with Rheumatoid Arthritis: A Cross-Sectional Study. 61
32295226 2020
22
Treatment for anxiety: Mindfulness meditation versus escitalopram (TAME): Design of a randomized, controlled non-inferiority trial. 61
32087339 2020
23
Neural correlates of NOS1 ex1f-VNTR allelic variation in panic disorder and agoraphobia during fear conditioning and extinction in fMRI. 61
32361414 2020
24
Cost-effectiveness of Practice Team-Supported Exposure Training for Panic Disorder and Agoraphobia in Primary Care: a Cluster-Randomized Trial. 61
31965532 2020
25
Investigating coregulation of emotional arousal during exposure-based CBT using vocal encoding and actor-partner interdependence models. 61
32237884 2020
26
A mobile application for panic disorder and agoraphobia: Insights from a multi-methods feasibility study. 61
31890640 2020
27
Modifiable risk and protective factors for anxiety disorders among adults: A systematic review. 61
31839417 2020
28
Prevalence, correlates and comorbidities of feeding and eating disorders in a nationally representative sample of Iranian children and adolescents. 61
31742760 2020
29
Mental disorders and total mortality after 20 years in an adult general population sample. 61
32115002 2020
30
The speed of progression towards obsessive-compulsive disorder. 61
32056748 2020
31
[Psychiatric and psychological support for an adolescent woman with chromosome 22 deletion syndrome and intellectual disability: a good outcome]. 61
32202548 2020
32
Panic attack provocation in panic disorder patients with a computer simulation. 61
31786029 2020
33
Anxiety disorders in outpatient clinics of epilepsy in tertiary care hospitals: A meta-analysis. 61
31874357 2020
34
Disgust and fear: common emotions between eating and phobic disorders. 61
29766462 2020
35
Developmental aspects of FXAND in a man with the FMR1 premutation. 61
31899609 2020
36
Effectiveness of mindfulness-based cognitive therapy in patients with anxiety disorders in secondary-care settings: A randomized controlled trial. 61
31774604 2020
37
Cognitive Behavioral Therapy, Mindfulness-Based Cognitive Therapy and Acceptance Commitment Therapy for Anxiety Disorders: Integrating Traditional with Digital Treatment Approaches. 61
32002935 2020
38
Specific relations of dimensional anxiety and manifest anxiety disorders during pregnancy with difficult early infant temperament: a longitudinal cohort study. 61
31927695 2020
39
Anxiety Disorders in the DSM-5: Changes, Controversies, and Future Directions. 61
32002930 2020
40
Role of Benzodiazepines in Anxiety Disorders. 61
32002938 2020
41
Well-Being Therapy in Anxiety Disorders. 61
32002942 2020
42
A Diagnostic-Oriented Screening Scale for Anxiety Disorders: The Center for Epidemiologic Studies Anxiety Scale (CESA). 61
32528370 2020
43
Current and Novel Psychopharmacological Drugs for Anxiety Disorders. 61
32002937 2020
44
Co-Morbidity between Major Depression and Schizophrenia: Prevalence and Clinical Characteristics. 61
32303036 2020
45
Variations in psychiatric morbidity between traumatized Norwegian, refugees and other immigrant patients in Oslo. 61
31961250 2020
46
Social phobia moderates the outcome in the EVIDENT study: A randomized controlled trial on an Internet-based psychological intervention for mild to moderate depressive symptoms. 61
31682137 2020
47
Severity of panic disorder, adverse events in childhood, dissociation, self-stigma and comorbid personality disorders Part 1: Relationships between clinical, psychosocial and demographic factors in pharmacoresistant panic disorder patients. 61
32112548 2019
48
Severity of panic disorder, adverse events in childhood, dissociation, self-stigma and comorbid personality disorders Part 2: Therapeutic effectiveness of a combined cognitive behavioural therapy and pharmacotherapy in treatment-resistant inpatients. 61
32200586 2019
49
Hypovitaminosis D is associated with negative symptoms, suicide risk, agoraphobia, impaired functional remission, and antidepressant consumption in schizophrenia. 61
30078128 2019
50
Psychiatric co-morbidity and asthma: A pilot study utilizing a free use tool to improve asthma care. 61
31922705 2019

Variations for Agoraphobia

Expression for Agoraphobia

Search GEO for disease gene expression data for Agoraphobia.

Pathways for Agoraphobia

Pathways related to Agoraphobia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.67 SLC6A4 MAOA HTR1A
2
Show member pathways
11.56 SLC6A4 SLC6A2 COMT
3
Show member pathways
11.07 SLC6A4 SLC6A2 MAOA
4
Show member pathways
10.8 MAOA COMT
5 10.78 SLC6A4 MAOA HTR1A
6
Show member pathways
10.61 MAOA COMT
7
Show member pathways
10.53 SLC6A4 MAOA COMT
8 10.47 MAOA COMT
9
Show member pathways
10.38 SLC6A4 SLC6A2 MAOA HTR1A COMT

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SCAR complex GO:0031209 8.62 WASF2 WASF1

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 neuropeptide signaling pathway GO:0007218 9.67 HCRTR1 GRPR GRP
2 Rac protein signal transduction GO:0016601 9.54 WASF2 WASF1
3 response to pain GO:0048265 9.52 SLC6A2 COMT
4 vasoconstriction GO:0042310 9.51 SLC6A4 HTR1A
5 catecholamine metabolic process GO:0006584 9.48 MAOA COMT
6 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 9.46 WASF2 WASF1
7 neurotransmitter catabolic process GO:0042135 9.43 MAOA COMT
8 dopamine catabolic process GO:0042420 9.4 MAOA COMT
9 monoamine transport GO:0015844 9.37 SLC6A4 SLC6A2
10 social behavior GO:0035176 9.33 SLC6A4 GRPR GRP
11 neurotransmitter reuptake GO:0098810 9.32 SLC6A4 SLC6A2
12 lamellipodium morphogenesis GO:0072673 9.26 WASF2 WASF1
13 psychomotor behavior GO:0036343 8.96 GRPR GRP
14 response to external biotic stimulus GO:0043207 8.62 GRPR GRP

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase A binding GO:0051018 9.32 WASF2 WASF1
2 neurotransmitter:sodium symporter activity GO:0005328 9.26 SLC6A4 SLC6A2
3 Arp2/3 complex binding GO:0071933 9.16 WASF2 WASF1
4 serotonin binding GO:0051378 8.96 SLC6A4 HTR1A
5 monoamine transmembrane transporter activity GO:0008504 8.62 SLC6A4 SLC6A2

Sources for Agoraphobia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....